Research

Siteman Investment Program Research Development Awards (SIP RDAs)

The SIP RDA will fund research projects twice per year. There are six mechanisms available:

  • CLINICAL TRIAL CATEGORY
    • New Clinical Trial Mechanism; up to $300,000 over 3 years
    • Existing Clinical Trial Mechanism; up to $200,000 over 2 years
  • PRE-R01 CATEGORY
    • Pre-R01 Mechanism; up to $200,000 over 2 years
    • Pre-R01 Mechanism with a Cancer Prevention & Control Emphasis; up to $200,000 over 2 years
    • Pre-R01 Mechanism for University of Missouri-Columbia Collaboration; up to $200,000 over 2 years
  • TEAM SCIENCE CATEGORY
    • Team Science Mechanism; up to $800,000 over 2 years

Complete information on each mechanism can be found in the Request for Applications (RFA) each cycle. A RFA will be announced twice per year on the following schedule:

 

GENERAL SIP DATE GUIDELINES* Cycle 1 Cycle 2
Announcement: January 15 July 15
Statement of Intent deadline: March 1 September 1
Full applications due: April 1 October 1
Anticipated decision notices: June 15 December 15
Start dates: July 1 January 1
*Dates may vary based on weekends, holidays, and other unforeseen circumstances.

Please consult the specific cycle’s RFA announcement for official deadlines.

2020 Cycle 2 Official Dates
Announcement: July 31, 2020
Statement of intent submission deadline: September 1, 2020
Application deadline: October 1, 2020
Anticipated decision notices: December 15, 2020
Start date: January 1, 2021

2020 Cycle 2 Application Documents

SIP RDA Request For Applications (RFA)
SIP RDA Application Cover Sheet – PDF version *preferred* (required – updated 09/2020)
SIP RDA Application Cover Sheet – word version (required – updated 09/2020)
SIP RDA Clinical Trial Category Budget Form (required – updated 07/2020)

Success Rates

Success rates have been computed over the span of SIP RDA by mechanism and include applications that were scientifically reviewed. Success rates are determined by dividing the number of applications funded by the total number of applications reviewed. The current success rate for the Pre-R01 mechanism is 24%.

Re-submissions are welcome and encouraged every cycle. The success rate for re-submissions across all mechanisms is 38%.

Previous awardees

Contact Jaclyn McGuire at Siteman Cancer Center for more information, mcguirej@wustl.edu.